Drug Profile


Alternative Names: DNA-C; DNA-HIV-C; DNA-HIV-PT123 vaccine; HIV clade C DNA vaccine; HIV DNA vaccine - EuroVac; HIV DNA vaccine - EuroVacc

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EuroVacc Foundation; GENEART; University of Regensburg
  • Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; HIV Vaccine Trials Network; International AIDS Vaccine Initiative; IPPOX Foundation; Medical Research Council; MRC/UVRI Uganda Research Unit on AIDS; National Institute of Allergy and Infectious Diseases; Novartis
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 12 Dec 2016 National Institute of Allergy and Infectious Diseases plans a phase I/IIa trial for HIV infections (Prevention, Combination therapy) in USA and South Africa (IM) (NCT02915016)
  • 22 Sep 2016 National Institute of Allergy and Infectious Diseases, HIV Vaccine Trials Network, IPPOX Foundation, Global Solutions for Infectious Diseases and EuroVacc Foundation withdraw a phase I trial, prior to enrolment, in HIV infections (Prevention) in USA and South Africa (NCT01927835)
  • 29 Sep 2015 No recent reports of development identified - Phase-I/II for HIV infections (Prevention, Monotherapy) in France and Switzerland (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top